Catalyst Pharmaceutical Partners (CPRX)

[homdance]

CPP-115: A Novel, Potent Molecule With
Superior Safety and Efficacy

$50-$100 MM market Opportunity for Infantile Spasms

• CPP-115-IS designed as oral therapy with better saf
ety &
tolerability to Vigabatrin
• Orphan drug indication in US & EU
• Leading therapies are not adequate
–
Acthar® Gel and Sabril®; generated $125MM
in 2012
• Affects 10,000-20,000 infants globally
–
5,000-10,000 in US
• Potential additional indications could increase mark
et
opportunity
–
Tourette’s Disorder (Large Orphan Indication)
• Phase I/II study ongoing at Mt. Sinai School of Medicin
e
• Top line results 1H 2014
–
Post-Traumatic Stress Disord